Business

The Readout Elaine Chen

STAT Plus: Hims takes a blow from Lilly’s vial news

A STAT Investigation Lizzy Lawrence, Casey Ross, Bob Herman, and Tara Bannow

STAT Plus: UnitedHealth pledged a hands-off approach after buying a Connecticut medical group. Then it upended how doctors practice

Exclusive Bob Herman

STAT Plus: Centene eliminates brokers’ commissions for Medicare drug plans

The Readout Elaine Chen

STAT Plus: Pfizer and Lilly want to sell you drugs directly

The Readout Meghana Keshavan

STAT Plus: A Galapagos investor signals impatience with its turnaround efforts

Health tech Katie Palmer and Lizzy Lawrence

STAT Plus: Continuous glucose monitoring for the masses is here. Are we ready for it?

Business Bob Herman

STAT Plus: Federal judge blocks noncompete ban, and FTC considers appeal

Business Bob Herman

STAT Plus: Peter Orszag wants the FTC and DOJ to stop challenging ‘vertical’ health care mergers

The Readout Meghana Keshavan

STAT Plus: Is pharma still fearful of the Inflation Reduction Act?

The Readout Elaine Chen

STAT Plus: We have mpox vaccines now. But how will they be distributed?

The Readout Elaine Chen

STAT Plus: Syros shares battered after it stops leukemia trial

Health tech Mario Aguilar

STAT Plus: Otsuka prices depression digital therapeutic to make it widely accessible, says it’ll lose money

The Readout Elaine Chen

STAT Plus: Atai advances oral psychedelic in depression

The Readout Meghana Keshavan

STAT Plus: A tough week for MDMA-assisted psychotherapy

Health Isabella Cueto

What’s in a drink? U.S. regulators consider new alcohol label, but health advocates want even more

The Readout Meghana Keshavan

STAT Plus: Why did Novo pull heart failure paperwork for Wegovy?

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: A strong start for Madrigal’s MASH drug launch

The Readout Meghana Keshavan

STAT Plus: Sarepta CEO: We’re ‘pretty brilliant’

Business Tara Bannow

STAT Plus: Orlando Health, a $6 billion Florida powerhouse, is expanding into Alabama

The Readout Elaine Chen

STAT Plus: A new drug for glioma means a windfall for Agios

A STAT Investigation Casey Ross, Lizzy Lawrence, Bob Herman, and Tara Bannow

STAT Plus: Health Care's Colossus: How UnitedHealth turned a questionable artery-screening program into a gold mine

Business Rachel Cohrs Zhang, Tara Bannow, and Bob Herman

STAT Plus: Tim Walz stood up to corporate health care. Mayo Clinic was a powerful exception

The Readout Elaine Chen

STAT Plus: The exclusive biotech stories you need to read

The Readout Meghana Keshavan

STAT Plus: FDA ad comm favors Zevra’s Niemann-Pick drug

The Readout Elaine Chen

STAT Plus: Moderna is still in a Covid hangover

Hospitals Tara Bannow

STAT Plus: UnitedHealth and HCA clash over hospital chain’s rates in ‘battle of the giants’

Business Bob Herman

STAT Plus: Private equity firms to acquire health care billing and payments firm R1 in $8.9 billion deal

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: On Andrew Left and the government’s fraud case

The Readout Elaine Chen

STAT Plus: venBio raises $528 million for its fifth fund